Androgen deprivation-mediated cytoreduction before interstitial brachytherapy for prostate cancer does not abrogate the elevated risk of urinary morbidity associated with larger initial prostate volume
To access this article, please choose from the options below
These data were presented as an oral abstract at the 2005 Annual Meeting of the European Society for Therapeutic Radiology and Oncology (ESTRO).
PII: S1538-4721(07)00246-2
doi:10.1016/j.brachy.2007.08.007
© 2007 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
